表紙
市場調查報告書

骨髓移植排斥反應:開發中產品分析

Bone Marrow Transplant Rejection - Pipeline Review, H1 2019

出版商 Global Markets Direct 商品編碼 372673
出版日期 內容資訊 英文 653 Pages
訂單完成後即時交付
價格
Back to Top
骨髓移植排斥反應:開發中產品分析 Bone Marrow Transplant Rejection - Pipeline Review, H1 2019
出版日期: 2019年05月21日內容資訊: 英文 653 Pages
簡介

骨髓移植排斥反應是幹細胞或骨髓移植後引發的併發症。是新移植的捐贈者細胞,攻擊接收移植者的身體之反應。前兆有胸部疼痛,發冷,血壓降低,發燒,臉紅,味覺異常,頭痛,蕁麻疹,噁心,疼痛,呼吸急促等。治療可使用免疫抑製藥。

本報告提供骨髓移植排斥反應的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

骨髓移植排斥反應 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/研究機關研究中的產品

治療藥的開發企業

  • AbbVie Inc
  • AbGenomics International, Inc.
  • Actelion Ltd
  • Alexion Pharmaceuticals Inc
  • Amunix Operating Inc.
  • Apceth GmbH & Co. KG
  • arGEN-X BV
  • Athersys, Inc.
  • Bellicum Pharmaceuticals, Inc.
  • Bio-Cancer Treatment International Limited
  • Biogen Inc
  • Boryung Pharmaceutical Co., Ltd.
  • Bristol-Myers Squibb Company
  • Cantex Pharmaceuticals, Inc.
  • Capricor Therapeutics, Inc.
  • Cell Source, Inc.
  • Cell2B S.A.
  • CellECT Bio, Inc.
  • Cleveland BioLabs, Inc.
  • Compugen Ltd.
  • Cynata Therapeutics Limited
  • Cytodyn Inc.
  • Dompe Farmaceutici S.p.A.
  • Dr. Falk Pharma GmbH
  • Escape Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fate Therapeutics, Inc.
  • Generon (Shanghai) Corporation Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Idera Pharmaceuticals, Inc.
  • ImmuNext, Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • Kadmon Corporation, LLC
  • Kamada Ltd.
  • Kiadis Pharma N.V.
  • Kymab Limited
  • 杏林藥業
  • MacroGenics, Inc.
  • Mallinckrodt Plc
  • Medsenic
  • Mesoblast Limited
  • Millennium Pharmaceuticals Inc
  • Neopharm Ltd.
  • Nohla Therapeutics Inc.
  • Novartis AG
  • OncoImmune, Inc.
  • OSE Immunotherapeutics
  • Pharmicell Co., Ltd.
  • Pluristem Therapeutics Inc.
  • REGiMMUNE Corporation
  • Rigel Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.
  • Seattle Genetics, Inc.
  • Seres Therapeutics, Inc.
  • Sigmoid Pharma Limited
  • Spherium Biomed S.L.
  • Taiga Biotechnologies, Inc.
  • 武田藥品工業
  • Targazyme, Inc.
  • Therapix Biosciences Ltd
  • Tobira Therapeutics, Inc.
  • Vault Pharma Inc.
  • Xenikos B.V.
  • ZIOPHARM ONCOLOGY, Inc.

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11164IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H1 2019, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape.

Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. Treatment includes immunosuppressive drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 11, 34, 14, 2, 47, 6 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 12 and 1 molecules, respectively.

Bone Marrow Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bone Marrow Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bone Marrow Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bone Marrow Transplant Rejection (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Bone Marrow Transplant Rejection - Overview
  • Bone Marrow Transplant Rejection - Therapeutics Development
  • Bone Marrow Transplant Rejection - Therapeutics Assessment
  • Bone Marrow Transplant Rejection - Companies Involved in Therapeutics Development
  • Bone Marrow Transplant Rejection - Drug Profiles
  • Bone Marrow Transplant Rejection - Dormant Projects
  • Bone Marrow Transplant Rejection - Discontinued Products
  • Bone Marrow Transplant Rejection - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Bone Marrow Transplant Rejection, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by AbbVie Inc, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by AbGenomics International Inc, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Alpine Immune Sciences Inc, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Amgen Inc, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by AnaptysBio Inc, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by apceth Biopharma GmbH, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Aptevo Therapeutics Inc, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Athersys Inc, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Bellicum Pharmaceuticals Inc, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Biocon Ltd, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Biogen Inc, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Bristol-Myers Squibb Co, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Capricor Therapeutics Inc, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Cell Source Inc, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Cell2B Advanced Therapeutics SA, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Cellect Biotechnology Ltd, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Cellective BioTherapy Inc, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Cellix Bio Pvt Ltd, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Clinigen Group Plc, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Compugen Ltd, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by CSL Ltd, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by CTI BioPharma Corp, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Cynata Therapeutics Ltd, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Cytodyn Inc, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Eli Lilly and Co, H1 2019
  • Bone Marrow Transplant Rejection - Pipeline by Elsalys Biotech SA, H1 2019
  • Bone Marrow Transplant Rejection - Dormant Projects, H1 2019
  • Bone Marrow Transplant Rejection - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Bone Marrow Transplant Rejection, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Top 10 Routes of Administration, H1 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2019
  • Number of Products by Top 10 Molecule Types, H1 2019
  • Number of Products by Stage and Top 10 Molecule Types, H1 2019
Back to Top